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Abstract
Direct to consumer advertising (DTCA) of prescription medicines has generated considerable controversy
in both New Zealand and the United States, the only two countries that currently permit promotion
ofrestricted medicines. Arguments against DTCA include the effect this may have on doctor-patient
relationships, its implications for drug costs, and the extent to which it fully informs potential patients.
Conversely, proponents of DTCA claim that it increases knowledge of a variety of common medical
conditions, thus fostering earlier diagnosis and better compliance with treatments. However, although
arguments for and against DTCA have merit, neither side has supported its position with empirical
evidence. In particular, the extent to which DTC promotions communicate effectively and achieve their
objective of improving wider consumer knowledge remains unclear. This paper critically evaluates the
alleged effects of DTCA and outlines our research agenda, which is designed to bridge current knowledge
gaps and provide a more informed basis for public policy decisions.
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Abstract
Direct to consumer advertising (DTCA) of prescription medicines has generated
considerable controversy in both New Zealand and the United States, the only two
countries that currently permit promotion of restricted medicines. Arguments against
DTCA include the effect this may have on doctor-patient relationships, its implications
for drug costs, and the extent to which it fully informs potential patients. Conversely,
proponents of DTCA claim that it increases knowledge of a variety of common medical
conditions, thus fostering earlier diagnosis and better compliance with treatments.
However, although arguments for and against DTCA have merit, neither side has
supported its position with empirical evidence. In particular, the extent to which DTC
promotions communicate effectively and achieve their objective of improving wider
consumer knowledge remains unclear. This paper critically evaluates the alleged effects
ofDTCA and outlines our research agenda, which is designed to bridge current
knowledge gaps and provide a more informed basis for public policy decisions.

Introduction
Only New Zealand and the United States currently permit direct-to-consumer advertising
(DTCA) of prescription medicines, a regulatory initiative that has attracted trenchant
criticism in both countries. In New Zealand, DTCA arguably evolved because statutes
governing the promotion of medicines did not specifically prohibit it. Other countries
(for example, Australia, Canada and EU nations) are considering relaxing their
restrictions on DTCA, in part motivated by regulators' awareness ofthe fact that many
consumers are already exposed to u.S.-originated DTCA through the Internet (Erickson,
2000). However, the specific impetus to develop DTC arose from three sources.
First, pharmaceutical companies have found it increasingly difficult and expensive to
reach doctors (Morris and Griffen, 1992). The ability to communicate directly with
potential end-users has thus enabled them to avoid the clutter now complicating
communication with health professionals. Second, consumers' interest in the
management of their health care has also increased. Pharmaceutical companies have
thus argued that DTCA enables consumers to access information about health care
options available to them, and thus contributes to a more knowledgeable and healthier
society. Finally, some researchers have argued that pharmaceutical companies' motives
may be less altruistic than financial For example, Sheffet and Kopp (1990) and Levitt
(1995) have argued that the need to generate a return on research and development
investments, in particular, created a powerful stimulus for DTCA. This need is
particularly acute in countries such as New Zealand, where the proportion of drugs that
attract government subsidies is lower than in countries that do not permit DTCA.
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Whatever motives underpin DTCA, its presence has generated controversy as drug
manufacturers, health professionals and regulators debate whether, and in what form,
OrCA should be permitted. In this paper, we ftrst critically evaluate key elements of the
OrCA debate occurring in both Australia and New Zealand. We then outline a research
agenda we are pursuing that will test many of the competing views about DTCA's effects
and, in so doing, provide a more robust foundation for public policy formation.

The Direct To Consumer Advertising Debate
Arguments over DTC have centred on three areas of contention. First, the ethics of
promoting restricted medicines to potential end-users who require a prescription before
they can obtain the drug (Davis, 2001). Second, the effects DTCA may have on
government allocated pharmaceutical budgets, which arguably struggle to meet current
demand without having also to accommodate the DTCA generated demand (pHARMAC,
2001). Third, the quality of information provided and consumers' ability to comprehend
this (Morris, Brinberg, Klimberg, Rivera and Millstein, 1986). In particular, the
emotional appeals used in some advertisements, together with a lack of detailed risk
information, have fuelled concerns that some DrCA does not meet the high standards of
social responsibility prescribed for it.

Doctor-Patient Relationships
Ooctors and health professionals have traditionally opposed nTCA because they believe
it disrupts the relationships doctors have with their patients (Lexchin, 1999; Mansfteld,
1999; Reast and Carson, 2001). That is, they fear that patients may demand advertised
drugs, when these might not suit them, or where other alternatives, such as "green"
prescriptions, could prove more effective (Mintzes, Barer, Kravitz, Kazanjian, Bassett,
Lexchin, Evans, Pan and Marion, 2002. A US telephone survey of 1,222 consumers
found that 32% of consumers who saw an advertisement for a prescription drug talked
with their doctor about the medication, with 26% of those asking for a speciftc medicine
and 71 % of these requests being granted (Findlay, 2002). Although most patients accept
their doctor's advice, there is some anecdotal evidence that a small proportion do not, and
that these latter patients have gone on to seek prescriptions from less scrupulous
prescribers, or from alternative sources such as the internet (Lexchin, 1999). However,
studies exploring the effect of DTC on patients' relationship with their doctors reveal
little evidence of dissatisfaction from patients' perspective (though neither do they
completely dispel the existence of "doctor-shopping") (Aitken, 2002).
Furthermore, doctors' initial opposition to DrCA in New Zealand appears to have waned
following its introduction, which may suggest their concerns were not realised. For
example, surveys of doctors reveal that their reaction to DTCA has mellowed, and
submissions by doctors' professional associations to DTCA reviews have recognised that
DrCA may foster more informed discussions between patients and doctors (NZMA,
2000; RCNZGP, 2000). Nevertheless, although this evidence suggests a growing
recognition that DTCA can improve consumers' knowledge, doctors remain concerned
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about some of the creative themes used and the lack of risk information provided in
television advertisements (Maguire, 1999).
Although one research trajectory could assess doctors' views ofDTCA, this research
appears likely to provide little more information than that currently available from
industry group submissions or publications. Thus, while further research into this
question may help to clarify the existence and level of any tension, it is unlikely that this
will produce a clear public policy outcome. For example, identifying any causal role
attributable to DTCA is well beyond the scope of such research. Nor will this be able to
address wider questions about how doctors ought to manage their relationships with
patients. Instead, it is more logical to explore doctors' concerns over the communication
effectiveness ofDTCA, a point we discuss in more detail below.

Fiscal Implications of DTCA
The second concern raised relates to the fiscal implications of DTCA. Where DTCA
increases demand for more expensive drugs at the expense of cheaper generic drugs, it
may escalate the overall pharmaceutical drug bill (Wilkes, Bell and Kravitz, 2000). In
the US for example, 48% of the $21 billion increase in prescription drug sales between
1999 and 2000 came from the 50 most heavily advertised drugs, out of the approximately
9,850 available on the U.S. market; and prescriptions for these 50 drugs increased by
24.6% compared to just 4.3% for all other drugs (Findlay, 2002). Furthermore, drug
companies may use evidence of increased consumer demand for branded unsubsidised
drugs to argue that drug funders should subsidise these drugs.
The evidence relating to these claims is more limited, and few, if any econometric
analyses have considered whether DTC creates or alleviates pressure on the drugs'
budget. In support of the latter claim, some researchers have argued that DTC creates a
wider awareness of health issues, which fosters prompter diagnosis and treatment
(Aparasu, 2000; Calfee, 2002). This, in turri, reduces the need for the more expensive
interventions required when a condition becomes acute. In addition, some researchers
have suggested that DTCA increases salience ofthe promoted brand, thereby fostering
treatment compliance and reducing the costs resulting from inadequate compliance
(Calfee, 2002).
Both arguments appear plausible; however, there is very little evidence to support either
ofthese potential effects. We plan to model DTCA promotions and prescribing
behaviour to explore the relationship between DTCA and drug expenditure and longerterm savings that may be attributable to DTCA. This work will clarify the arguments
about DTCA's effects and, in particular, its fiscal implications.

Consumers' Understanding ofDTCA
The third concern raised relates to consumers' understanding ofDTCA promotions.
Detractors ofDTCA have argued that lay consumers lack the knowledge necessary to
understand and interpret DTCA (ACP & ASIM, 2001). In particular, they argue that only
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those with detailed technical training can appreciate the interaction between the promoted
drug and any other medication consumers may take. Consumers who are inadequately
informed about a particular drug's wider characteristics may thus over-estimate its
relevance to their condition and fail to appreciate the risks associated with it. As a result,
some consumers may visit their doctors specifically to request drugs that they cannot
safely take, thus wasting their time and money (Mansfield, 1999).
Conversely, proponents ofDTCA suggest that consumers who seek information about an
advertised drug have typically recognised undiagnosed symptoms shown in
advertisements (RMI, 2000). Consumers therefore do not require a detailed
understanding of a particular drug's properties in order to be able to empathise with the
specific symptoms depicted. Although they may mention the promoted drug, if this did
not suit their condition, doctors would be able to prescribe an alternative treatment
(including a non-drug option). Whatever the outcome, DTCA would have promoted the
earlier detection of a condition and this, in turn, may reduce the likelihood of more
expensive interventions at a later date. Furthermore, FDA research suggests that very
few patients specifically visit their doctor to discuss a DTC promotion; those who discuss
a drug they have seen promoted typically do so in the context of a visit for a different
condition (Aitken, 2002; Calfee, 2002).
Opponents ofDTCA have also argued that the promotions are excessively emotive, and
that they emphasise benefit information while providing inadequate guidance about the
risks associated with a particular drug. Thus consumers may be swept away by the
perceived benefits of a product and yet have little comprehension of the risks, side
effects, or contraindications associated with that drug. A recent U.S. study that analysed
67 DTCA magazine ads found that 67% used emotional appeals and only 13% provided
data (rather than vague qualitative descriptions) on the benefits of the medication
(Woloshin, Schwartz, Tremmel and Welch, 2001). Clearly, consumers need to have
sufficient knowledge of a drug to make an informed choice whether to seek additional
information. Where the details provided do not support this choice, the advertising has
arguably failed to meet a high standard of social responsibility (a feature of the legislation
or self-regulatory codes in those countries where it is permitted).
Finally, the format in which drug information is presented has also attracted criticism. In
New Zealand, advertisers must include information about the drug's active ingredients,
its indications, contra-indications, adverse effects and risk factors. In addition, they must
specify its status, include standard precautionary information and outline further contact
details. While this information can be easily incorporated into print advertisements, it
has the potential to overwhelm television advertisements, which may screen for only 30
seconds. To ensure adequate time for the creative content of an advertisement, these
technical details typically appear in an end-screen that features for five seconds. Given
the amount of information DTC promotions are legally required to contain, consumers
may have very little time in which to absorb and comprehend key details about the
promoted drug. Research examining consumers' knowledge of key drug properties
following exposure to an advertisement suggests many have an inadequate understanding
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of the characteristics that would determine the drug's suitability for their condition
(Morris et aI, 1986).
In summary, opponents ofDTCA argue that DTC promotions fail to communicate
important information, leaving consumers inadequately prepared to assess the relevance
or suitability of a drug for their range of conditions. They thus argue that, because a
little knowledge can be a dangerous thing, regulators should ban DTCA or, at the very
least, impose tighter regulations on it.
Overall, these arguments suggest that further research into the communication
effectiveness of DYC promotions is urgently required. At present, our research is
exploring the amount and type of information conveyed in DTC promotions, and the
format used to convey this, to identify a "best practice" model. We are also examining
consumers' knowledge of further information sources (such as free phone numbers) and
recall of drugs' key risks and contraindications. In addition, our work assesses
consumers' uptake of benefit and risk information, and the extent to which this reflects
the "fair balance" criterion DTCA must address. We will also explore how different
creative themes affect uptake of information, again with a view to identifying a range of
optimal communication formats. This work has specific public policy implications and
will help regulators determine whether and how to continue these promotions.

Conclusions
While there are several avenues of research in DTCA that researchers could pursue, we
suggest there is little to be gained by pursuing some ofthese. In particular, further work
into health professionals' attitudes toward DTCA will not support public policy
decisions, which need to consider effects rather than emotions. Researchers thus need to
examine how effectively DTC promotions communicate, and how changes in the
structure and content ofDTC advertisements could achieve higher standards of
communication. This work would address issues raised by health professionals, whose
chief concern relates to inadequately informed consumers. Furthermore, in New Zealand,
where government regulators have taken a strong interest in DTCA, such research would
provide valuable public policy insights. In particular, it could help establish an empirical
framework that advertisers could use to help ensure their promotions communicated
clearly and effectively, and actively contributed to a better-informed consumer sector.
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